[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Universitas Sebelas Maret\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":97},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,60],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":26,"conditions":27,"keywords":32,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":48,"lastUpdatePostDateStruct":49,"startDateStruct":52,"completionDateStruct":54,"leadSponsor":56,"locationsCount":59},"100629468","phase-2-the-effect-of-oral-dlbs1033-in-patients-with-diabetic-polyneuropathy-100629468",false,"NCT07475065","The Effect of Oral DLBS1033 in Patients With Diabetic Polyneuropathy","The Effect of Oral DLBS1033 as Adjuvant Therapy on Inflammatory Biomarkers, Neuroregeneration Biomarkers, and Disease Severity in Patients With Diabetic Polyneuropathy: A Randomized Controlled Trial (An Evaluation of Changes in TCNS, TNF-α, NGF, and Sensory Nerve Conduction Study of the Sural Nerve)","Inclusion Criteria:\n\n* Adults aged 40-60 years diagnosed with diabetic polyneuropathy by a neurologist or neurology resident.\n* Patients with HbA1c levels between 7-10% within the past 30 days.\n* Willing to participate and able to sign the informed consent form.\n\nExclusion Criteria:\n\n* Pregnant, breastfeeding, or planning pregnancy.\n* History of other neurological diseases such as stroke, myelopathy, alcoholic neuropathy, or compressive radiculopathy.\n* Significant renal impairment (creatinine \\> 1.5× upper limit of normal), hepatic impairment (SGOT or SGPT \\> 3× upper limit of normal), or severe cardiac disease (NYHA class III-IV heart failure).\n* History of alcohol consumption for ≥ 5 consecutive years.\n* Heavy smoker (Brinkman Index \\> 600).\n* Known allergy or intolerance to DLBS1033.\n* Autoimmune disease, malignancy, or acute and\u002For chronic inflammatory conditions other than diabetic polyneuropathy.\n* Participation in another interventional pharmacological clinical study within 30 days prior to screening.\n* Currently taking anti-inflammatory and\u002For antioxidant medications.","ALL","40 Years","60 Years",{"count":20,"type":21},34,"ESTIMATED","INTERVENTIONAL",[24,25],"PHASE2","PHASE3","This study aims to evaluate whether oral DLBS1033 can improve clinical symptoms and biological markers of nerve damage in adults with diabetic polyneuropathy. The trial enrolls patients with type 2 diabetes who show clinical signs of peripheral nerve injury.\n\nParticipants will receive either DLBS1033 as adjuvant therapy or standard therapy alone for 28 days. The study will compare changes in neuropathy severity (Toronto Clinical Neuropathy Score), inflammatory biomarkers (TNF-α), neuroregeneration biomarkers (Nerve Growth Factor), and sensory nerve conduction parameters of the sural nerve between the two groups. Blood tests, clinical assessments, and nerve conduction studies will be performed at baseline and follow-up visits. Participants will also report any symptoms or adverse events throughout the study.",[28,29,30,31],"Diabetic Polyneuropathy","Peripheral Nervous System Diseases","Peripheral Neuropathy","Diabetes Mellitus",[33,34,35,36,37,38,39,40,41,42,43,44,45,46],"DLBS1033","lumbrokinase","diabetic polyneuropathy","peripheral neuropathy","Toronto Clinical Neuropathy Score","TNF-α","TNF-alpha","Nerve Growth Factor","sural nerve","nerve conduction study","NCS","EMG","ENMG","Electromyography","NOT_YET_RECRUITING","2026-03-13",{"date":50,"type":51},"2026-03-16","ACTUAL",{"date":53,"type":21},"2026-03-01",{"date":55,"type":21},"2026-06-30",{"name":57,"class":58},"Universitas Sebelas Maret","OTHER",1,{"id":61,"slug":62,"hasResults":11,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":66,"eligibilityCriteria":67,"healthyVolunteers":68,"sex":16,"minAge":69,"maxAge":70,"enrollmentInfo":71,"targetDuration":4,"studyType":22,"phases":73,"briefSummary":75,"conditions":76,"keywords":84,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":59},"100595994","empowering-knowledge-self-testing--resilience-through-innovative-methods-for-hiv-100595994","NCT07039682","Empowering Knowledge, Self-Testing & Resilience Through Innovative Methods for HIV","Developing a Digital-Based Education and Self-Screening Model to Improve Knowledge, Self-Awareness, and HIV Testing Coverage Among Adolescents","EKSTRIM","Inclusion Criteria:\n\n* Adolescents aged 15-17 years\n* Reside or attend school in the Yogyakarta area\n* Currently enrolled in one of the participating high schools\n* Able to read and understand Bahasa Indonesia\n* Own or have regular access to a smartphone or digital device with internet connectivity\n* Provide informed assent to participate in the study\n* Have obtained written parental or guardian consent\n\nExclusion Criteria:\n\n* Adolescents outside the 15-17 age range\n* Unable to access digital devices or internet independently\n* Previously diagnosed with HIV (as this study targets prevention and self-screening among untested adolescents)\n* Unwilling or unable to provide informed assent or whose parents\u002Fguardians do not provide consent\n* Currently participating in another HIV-related intervention study",true,"15 Years","17 Years",{"count":72,"type":21},400,[74],"NA","The goal of this study is to learn whether a digital tool can help improve HIV knowledge, self-awareness, and testing among adolescents in Yogyakarta, Indonesia. The tool includes online HIV education, a self-assessment for HIV risk, and access to trained peer educators for support. The study will also explore how comfortable and willing adolescents are to use this kind of digital health service.\n\nThe main questions the study aims to answer are:\n\n* Can this digital tool help adolescents better understand HIV and their personal risk?\n* Will more adolescents be willing to get tested for HIV after using the tool?\n* What factors affect whether adolescents accept and use digital HIV services?\n\nResearchers will compare two groups of high school students:\n\n* One group will use the digital tool for 6 weeks\n* The other group will receive standard HIV education (not through the tool)\n\nParticipants will:\n\n* Answer surveys before and after the 6-week period\n* Learn about HIV through videos and interactive content\n* Use the tool to assess their personal HIV risk\n* Receive support from trained peer educators (online)\n\nThe researchers hope this study will lead to new ways of using technology to improve HIV prevention and testing for young people.",[77,78,79,80,81,82,83],"Human Immunodeficiency Virus (HIV) Infection","HIV Prevention","Adolescent Health","Digital Education Interventions","Digital Health Intervention","Health Education","HIV Stigma",[85,86,87,88],"hiv prevention","adolescent health","health education","digital intervention","2025-06-18",{"date":91,"type":51},"2025-06-26",{"date":93,"type":21},"2025-07-31",{"date":95,"type":21},"2025-12-31",{"name":57,"class":58},""]